Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus OMNIPAQUE 180.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus OMNIPAQUE 180.
CHOLOGRAFIN SODIUM vs OMNIPAQUE 180
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodipamide (cholografin sodium) is a radiographic contrast agent that opacifies the biliary ducts and gallbladder by being excreted into bile via the hepatic organic anion transporter (OATP) and then concentrated in the gallbladder. It absorbs X-rays due to its iodine content, allowing visualization of the biliary tree.
Iodinated contrast agent that radiates X-rays due to high iodine content, attenuating X-ray beams and enhancing vascular/tissue contrast.
2-3 mL of 30% solution intravenously over 1-2 minutes, repeated if necessary up to a total of 10 mL.
Intravenous: 50-200 mL of 180 mgI/mL (9-36 g iodine) administered as a bolus or infusion, depending on imaging procedure and patient size; typical CT dose: 100-150 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In severe renal impairment (CrCl < 30 mL/min), half-life may extend to 10-20 hours, requiring dose adjustment.
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment)
Primarily renal excretion via glomerular filtration and tubular secretion. Approximately 70-80% of the dose is excreted unchanged in urine within 24 hours. Biliary excretion accounts for less than 10%, with fecal elimination minimal.
Renal: >95% unchanged by glomerular filtration within 24 hours; Biliary/Fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent